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Background: Prostate cancer (PCa) is the most common male cancer in Europe and the US. The early diagnosis
relies on prostate specific antigen (PSA) serum test, even if it showed clear limits. Among the new tests currently
under study, one of the most promising is the prostate cancer gene 3 (PCA3), a non-coding mRNA whose level increases
up to 100 times in PCa tissues when compared to normal tissues. With the present study we contribute to the validation
of the clinical utility of the PCA3 test and to the evaluation of its prognostic potential.
Methods: 407 Italian men, with two or more PCa risk factors and at least a previous negative biopsy, entering the Urology
Unit of Regina Elena National Cancer Institute, were tested for PCA3, total PSA (tPSA) and free PSA (fPSA and f/tPSA) tests.
Out of the 407 men enrolled, 195 were positive for PCa and 114 of them received an accurate staging with evaluation of
the Gleason score (Gs). Then, the PCA3 score was correlated to biopsy outcome, and the diagnostic and prognostic utility
were evaluated.
Results: Out of the 407 biopsies performed after the PCA3 test, 195 (48%) resulted positive for PCa; the PCA3 score was
significantly higher in this population (p < 0.0001) differently to tPSA (p = 0.87). Moreover, the PCA3 test outperformed
the f/tPSA (p = 0.01). The sensitivity (94.9) and specificity (60.1) of the PCA3 test showed a better balance for a threshold
of 35 when compared to 20, even if the best result was achieved considering a cutoff of 51, with sensitivity and specificity
of 82.1% and 79.3%, respectively. Finally, comparing values of the PCA3 test between two subgroups with increasing Gs
(Gs≤ 6 versus Gs≥ 7) a significant association between PCA3 score and Gs was found (p= 0.02).
Conclusions: The PCA3 test showed the best diagnostic performance when compared to tPSA and f/tPSA, facilitating the
selection of high-risk patients that may benefit from the execution of a saturation prostatic biopsy. Moreover, the PCA3
test showed a prognostic value, as higher PCA3 score values are associated to a greater tumor aggressiveness.
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Prostate cancer (PCa) is the most common malignancy in
men of Western populations and one of the major burden
in public health [1], despite numerous efforts were made
attempting to clarify the various aspects of this disease
[2-4]. During the last years an increasing PCa incidence
has occurred, probably linked to the introduction of the
prostate specific antigen (PSA) determination in terms of
opportunistic screening [5]. The PSA test actually brought
to the diagnosis of a high number of asymptomatic and
preclinical forms of PCa, but it has not been associated
with a decrease in mortality, opening a wide debate on the
diagnostic utility of this test [6]. One of the main disad-
vantages of the PSA test is its low specificity, which causes
the execution of a high percentage of negative biopsies
(60-75%), especially in patients with total PSA (tPSA)
levels between 4 and 10 ng/ml [7,8]. A great effort is
therefore constantly turned to the research of new
markers capable to improve the PCa diagnosis, to identify
the asymptomatic and more aggressive forms and to re-
duce the number of biopsies, lowering the risk of pain,
bleeding and infection to many patients [9]. Among the
characterized biomarkers one of the most promising for
its diagnostic potential, is the Prostate Cancer gene 3
(PCA3). PCA3 (also known as DD3 or DD3PCA3) is lo-
cated on chromosome 9 and is transcribed into a non-
coding prostate-specific mRNA which is overexpressed in
tumor cells, from 60 to 100 times, when compared to the
normal prostate tissue [10]. The PCA3 test is based on the
quantification of the PCA3 mRNA on urine sample after
digital-rectal examination (DRE), using the methodology
of the transcription mediated amplification (TMA). The
obtained result is then normalized to the amount of PSA
mRNA, evaluated in the same urine sample, in order to
calculate the PCA3 score (PCA3 mRNA/PSA mRNA×
1000). To date, many studies have been performed and
most of them showed how the PCA3 test represents a use-
ful tool to predict PCa, but questions about the optimal
cutoff and the ability of PCA3 to predict tumor aggressive-
ness still remain highly controversial [11,12]. Here, we
report the results of the PCA3 test among an Italian
prospective cohort of high-risk PCa patients in order to
evaluate its actual clinical utility as a diagnostic test add-
itional and/or alternative to the PSA test. Moreover, best
PCA3 cutoff was assessed to better discriminate patients
with and without PCa. Finally, the correlation between the




Between November 2009 and May 2011, 407 consecu-
tive men with two or more risk factors for PCa and at
least a previous negative biopsy entered the UrologyUnit of Regina Elena National Cancer Institute. Risk fac-
tors for PCa could be: tPSA higher than 2,5 ng/ml, a fam-
ily history of PCa, a borderline DRE and the presence of
pre-neoplastic forms in a prior biopsy. None of the pa-
tients had a history for PCa and none was taking drugs
able to lower PSA since at least one month. Biopsies
evidencing pre-neoplastic forms, such as atypical acinar
proliferation (ASAP), low-grade prostatic intraepithelial
neoplasia (LGPIN) lesions or high grade PIN (HGPIN),
were classified as negative. Once tests were carried out,
patients were addressed more or less urgently towards a
saturation prostatic biopsy. To date, all patients underwent
a prostatic biopsy. This study was approved by the Ethics
Committee of Regina Elena National Cancer Institute
and a written informed consent was obtained from all
participants.
Sample processing
Blood samples were collected in tubes containing gel
and clot activator for serum separation (Vacutainer,
Becton-Dickinson, Franklin Lakes, NJ, USA). Samples
were centrifuged within 1 h at 2500 g for 15 min and
stored in aliquots at −80°C until processing. Serum tPSA
and fPSA were assessed with an electrochemilumines-
cence immunoassay (ECLIA) on fully-automated COBAS
6000 e601 module analyzer (Roche Diagnostics GmbH,
Penzberg, Germany), according to the manufacturer’s
specifications and using proprietary reagents. After blood
sampling, a prostatic massage was performed, always from
the same urologist and consisting in three digital pressure
per lobe, so 20–30 ml of urine were then collected in a
sterile urine container (Nalgene, Rochester, NY, USA) and
transferred into a specific transport tube (Progensa PCA3
Urine Specimen Transport Kit, San Diego, CA, USA) to
be stored at −80°C until processing. The PROGENSA
PCA3 assay (Gen-Probe Inc., San Diego, CA, USA) was
used to evaluate the PCA3 and PSA mRNA expression
levels in urine samples, in order to calculate the PCA3
score as the ratio of PCA3 to PSA mRNA × 1000. Both
urine and serum samples were collected and processed at
the Clinical Pathology Laboratories of the Regina Elena
National Cancer Institute. After samples testing, all pa-
tients gradually performed a saturation prostatic biopsy.
All tissue samples were collected and evaluated from the
Pathological Anatomy Unit of the Regina Elena National
Cancer Institute. If more than one neoplastic focus was
detected in the same tumor, the highest Gs was reported.
Statistical analyses
The association between variables was tested by Pearson's
Chi-square test or Fisher’s Exact test, when appropriate.
The continuous data as mean and standard deviation or
median and range was reported. Binary data was reported
as frequency and percentage values. Kruskal-Wallis or
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appropriate) were used for the comparisons. A p-value ≤
0.05 was considered statistically significant.
The receiver operating characteristic (ROC) curve
analysis was performed in order to find possible optimal
cut-offs capable of splitting patients in two groups and
for assess models predictive accuracy through the
estimation of the area under the curve (AUC), providing
specificity, sensitivity, negative and positive predictive
value (NPV and PPV), and the 95% confidence interval
(CI) for all possible threshold values and differences
between curves. The SPSS®(21.0) statistical program was
used for all the analyses.
Results
Out of the 407 men enrolled, all were tested for tPSA,
fPSA, and PCA3; moreover, all of them performed a
subsequent biopsy that revealed 195 (48%) tumors. For
both the PCa and non-PCa groups, data concerning the
median age, tPSA, f/tPSA and PCA3 values were summa-
rized in Table 1. Comparing PCa versus non-PCa men, no
difference in tPSA values were found (p = 0.87), while men
with PCa showed a lower median f/tPSA (p = 0.01) and a
significantly higher median of the PCA3 score (p < 0.0001),
compared to men without PCa (Figure 1). No association
with age was found.
To further evaluate the clinical significance of the
PCA3 test, six intervals of PCA3 score values versus
biopsy outcomes were chosen (Figure 2). Specifically,
PCA3 score values were parted in increasing ranges
(0–20, 21–35, 36–50, 51–70, 71–100 and >100) so the
number of PCa-positive biopsies for each interval was
evaluated. The probability to find a positive biopsy
strongly correlates with the PCA3 test, as the probabil-
ity to find a PCa-positive biopsy is higher at increased
PCA3 score values (p < 0.0001).
In order to characterize the best cutoff of the PCA3
test, the number of true negative (TN), true positiveTable 1 Number of PCa-positive and PCa-negative patients
and evaluation of the related distribution in terms of median
age, tPSA, f/tPSA and PCA3 score values
PCa non-PCa p value
Number (%) 195 (48) 212 (52) /
Age 71 ± 27 69 ± 31 0.33
(median ± SD)
tPSA (ng/ml) 7.53 ± 4.88 7.34 ± 5.87 0.87
(median ± SD)
f/tPSA 0.15 ± 0.07 0.18 ± 0.07 0.01
(median ± SD)
PCA3 score 82 ± 45 33 ± 26 <0.0001
(median ± SD)(TP), false negative (FN), and false positive (FP) at differ-
ent PCA3 scores were evaluated. Consequently, sensitiv-
ity and specificity, for each considered threshold, as well
as the PPV and NPV were calculated. Considering our
cohort, 35 overcomes 20 as PCA3 score cutoff, because
a better balance between sensitivity and specificity, as
well as higher PPV and NPV, were observed. However,
the best result was obtained from a PCA3 score thresh-
old of 51, that showed the best sensitivity, specificity,
PPV and NPV values (Table 2).
In addition, in order to compare the diagnostic
performance of the PCA3 and PSA tests, a ROC analysis
was performed (Figure 3). The area AUC was found to
be higher for the PCA3 test (0.865) when compared to
both tPSA (0.505) and f/tPSA (0.607).
Finally, the association between the PCA3 score and
the tumor aggressiveness, expressed in terms of Gs
score, was investigated (Table 3). The evaluation of the
histologic grade was perfectly assessable on 114 PCa
men. The tumor aggressiveness was split in two classes:
Gs ≤ 6 (that includes the lower grades) and Gs ≥ 7
(representing the most clinically significant cases). The
PCA3 score threshold of 51 (optimal for our cohort),
was exceeded from the 69% of men with Gs ≤ 6, but this
percentage was significantly higher (87.5%) for men with
Gs ≥ 7 (p = 0.02).
Discussion
The PSA limitations in PCa detection and classification
are well established [13,14]. Hereupon, the risk to under-
estimate patients with PCa because of normal PSA
levels, and, more often, to guide patients toward specialized
medical practices attempting to detect a small percentage
of clinically significant cancers, is very high. Moreover, it
has been shown how PSA fails to predict the lethal forms
of PCa [15]. Therefore, many independent studies aimed
to find and to validate new PCa biomarkers are being
performed.
The present study is based on an Italian cohort of 407
men with one or more previous negative biopsies; all of
them, belonging to a high risk population for PCa, were
addressed to a saturation prostatic biopsy after the
PCA3 test. This study succeeded in demonstrating that
the PCA3 test is a more sensitive test than the tPSA and
the f/tPSA tests in discriminating patients with and
without PCa (Table 1 and Figure 1). In fact, for our
cohort, the median tPSA value was similar between the
two subgroups (p = 0.87), while a significant difference
was found for the f/tPSA (p = 0.01); however, the best
result was obtained considering the different distribution
of the PCA3 score (p < 0.0001) between PCa and non-
PCa patients.
Although the PCA3 test seems to improve the prob-
ability to detect PCa, it is still unclear whether a not-
Figure 1 tPSA (A), f/tPSA (B) and PCA3 score (C) values for patients negative and positive for PCa.
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score, as well as if this test is able to detect a neoplasia
at its very initial stage; on the other hand, some reports
suggest that PCA3-mRNA can be also detected in
HGPIN lesions [16-18]. Although in this study LGPIN
and HGPIN reports were classified as negative, the
present data support the hypothesis that the probability
to find a PCa gets higher when the PCA3 score in-
creases. At a low PCA3 score, in fact, the percentage of
subjects with PCa was small (5.3% for PCA3 score be-
tween 0 and 20), while the percentage increased steadily
to reach the maximum when the PCA3 score exceeded
100 (p < 0.0001); in this case, in fact, PCa was found in
79% of patients (Figure 2).
One of the major opened questions about the PCA3
test, on the other side, regards the optimal cutoff useful
to discriminate patients with and without PCa. The
optimal threshold proposed by Gen-Probe Inc., using
the PROGENSA PCA3 assay, was 35, but several studies
suggested that this value could be modified, getting lower
or even higher, in a way that is probably dependent on the
population features. In this respect, the cutoff value of
20 seems to increase the PCA3 test sensitivity withoutFigure 2 Relationship between PCA3 score and the percentage
of positive biopsies.affecting the specificity [19-24]. Some studies demon-
strated that PCA3 is effective only after the first nega-
tive biopsy, however, a recently published meta-analysis
showed that PCA3 can be used for repeat biopsy to im-
prove accuracy of PCa detection, since a large number
of unnecessary biopsies can be avoided by using a PCA3
score cutoff of 20 [12,25]. To assess the best PCA3
score value, useful to discriminate those at a tumor
stage, the most commonly used thresholds were exam-
ined. In our cohort, in which a division between men
with one or more previous negative biopsies was not
prevented, the lowest specificity was found for 20
(33.3%) when compared to 35 (60.1%), while the sensi-
tivity resulted very similar (97.9% and 94.9%, respect-
ively). Even if a threshold of 35 showed a better balance
between sensitivity and specificity, the best performance
was reached considering a threshold of 51, showing sen-
sitivity and specificity of 82.1% and 73.3%, respectively
(Table 2). An optimal cutoff higher than 35 was found
also in other independent prospective studies, where it
showed the ability to prevent a larger number of un-
necessary biopsies, highlighting more firmly on those
patients who need a fast treatment [22,23,26]. These re-
sults were confirmed by the ROC analysis, as comparing
the area under the curve for PCA3, tPSA, and f/tPSA
tests we found values of 0.865, 0.505 and 0.607, respect-
ively. These data indicate that the PCA3 test showed
the best performance for the PCa diagnosis for our
cohort of men (Figure 3).Table 2 Sensitivity, specificity, positive predictive value




Sensitivity 97.9 94.9 82.1
Specificity 33.3 60.1 79.3
PPV 47.8 68.5 78.4
NPV 57.4 92.8 82.8
Figure 3 ROC analysis with evaluation of the corresponding
AUC for tPSA (0.505), f/tPSA (0.607) and PCA3 score (0.865).
Merola et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:15 Page 5 of 6Lastly, a possible correlation between the PCA3 score
and the tumor aggressiveness, expressed in terms of Gs,
was investigated. Subjects with organ-confined PCa and
Gs ≥ 7 have a worst prognosis than those with Gs ≤ 6,
even following radical prostatectomy or radiation therapy
[27-29]. To recognize a low grade from a more aggressive
PCa is therefore essential for therapeutic purposes, but
currently the only way to discriminate patients with low
or high grade PCa is to perform a biopsy. The possibility
of using the PCA3 test as a prognostic marker is desirable,
but the possibility to evaluate tumor aggressiveness by the
PCA3 test is openly debated [17,21,23,26,30-34]. Indeed,
the wide range of results obtained in previous studies may
be due to different experimental conditions and may re-
flect the selected cohort features. In fact, the use of urine
sediments or whole urine samples, collected before or
without a previous DRE, can give rise to different results
that are not often comparable in judging the prognostic
value capabilities of the PCA3 test. On the other hand, the
characteristics of the screened population could be im-
portant, indeed the choice to enroll only patients with a
certain risk for PCa, or depending on the number of previ-
ous biopsies, can drive data towards an easier or less easy
association between the result of the PCA3 test and the
tumor aggressiveness.Table 3 Correlation between tumor aggressiveness,
expressed in terms of Gleason score (Gs), and the PCA3
score (p = 0.02) in a subgroup of patients with PCa
assessable histological characterization (n = 114)
PCA3 score
≤51 >51
Gs ≤ 6 (%) 13 (31) 29 (69)
Gs ≥ 7 (%) 9 (12.5) 63 (87.5)The patients enrolled in this study were selected ac-
cording to the presence of persistent risk factors for PCa
with at least a previous negative biopsy. We evaluated,
among patients with an assessable tumor grading (n = 114),
those who exceeded the PCA3 score value of 51 (optimal
for our cohort) showing, at the same time, a low grade
PCa, i.e. Gs ≤ 6, or a higher grade PCa, represented by
Gs ≥ 7 (Figure 3). For our cohort of men, a correlation be-
tween the PCA3 level and the PCa grading was actually
found; indeed, the percentage of patients with a PCA3
score higher than 51 and a Gs ≤ 6 was 69%, while the per-
centage of patients with a PCA3 score higher than 51 and
a Gs ≥ 7 (87.5%) was significantly higher (p = 0.02). These
data strengthen the hypothesis that the PCA3 test could
recognize, among PCa subtypes, those more aggressive
that may benefit from the resolutive radical prostatectomy
surgery.
Conclusions
The present study was conducted on subjects with at
least a previous negative prostatic biopsy and with two
or more persistent risk factors for PCa, resulting there-
fore good candidates for a further biopsy. Here, we re-
port that the PCA3 score shows a great diagnostic
accuracy compared to both tPSA and f/tPSA tests;
moreover, a high PCA3 score corresponds to an in-
creased probability to find a positive biopsy. Our data
suggest that the PCA3 test could predict a PCa and
allow urologists to more easily select, among high-risk
patients, those who may benefit from a saturation pros-
tatic biopsy. Even more interesting is the finding of a
correlation between PCA3 score and tumor aggressive-
ness, expressed in terms of Gleason score, that strength-
ened the hypothesis of PCA3 as an effective prognostic
marker, able to discriminate, among cancers, those less
significant that may directly enter the active surveillance
protocols, lowering the economic effort for PCa diagno-
sis supported from public health.
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